Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease
Objective response rate 33% (23%-44%) 29% (19%-41%) RR 1.21 (0.88-1.86) 24% (11%-40%) 19% (11%-30%) RR 1.56 (1.19-2.04)ICI discontinuation 15% (10%-20%) 5% (2%-9%) RR 1.61 (1.12-2.31)10% (5%-14%) 3% (0%-8%) RR 2.22 (0.77-6.41)
Authors
- Nagashree Seetharamu (ORCID: https://orcid.org/0000-0002-3282-7622)
- Margaret Locke (ORCID: https://orcid.org/0000-0002-5162-1638)
- Adit Singhal
- Wint Yan Aung (ORCID: https://orcid.org/0000-0003-3372-9175)
Institutions
- Northwell Health (US)
Publication Details
- Journal
- Journal of Cancer Biology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.46439/cancerbiology.6.068
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00